![]() Colchicine in combination with grapefruit or Seville orange juice was well tolerated. Seville orange juice also caused, on average, a 1-hour delay in Tmax. When colchicine was administered with Seville orange juice, a moderate inhibitor, Cmax and AUC were decreased by ∼24% and ∼20%, respectively. Although it is considered to be a moderate concentration-dependent CYP3A4 inhibitor, grapefruit juice did not significantly affect the pharmacokinetic parameters of colchicine. AEs were coded according to corresponding MedDRA-coded system organ classes.įorty-four subjects received either grapefruit juice (72.7% male 90.9% white) or Seville orange juice (62.5% female 100% white). All subjects were monitored for adverse events (AEs) throughout the confinement portion of the study and were queried at the outpatient visits. In each study, blood samples for pharmacokinetics were collected before dosing with colchicine and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours postdose. Pharmacokinetic data were obtained following a single 0.6-mg dose of colchicine before the administration of juice and again following a single 0.6-mg dose of colchicine on the final day of juice administration. Undiluted juice (240 mL) was administered twice daily for 4 days. Healthy volunteers were enrolled in 2 open-label, Phase I studies. Two Phase I studies assessed the effects of multiple daily consumptions of Seville orange juice or grapefruit juice on the pharmacokinetic properties of colchicine in healthy volunteers. Severe toxicities in patients consuming these juices while taking other drugs metabolized through these pathways have been reported. Two of the furocoumarins in grapefruit juice and Seville orange juice can inhibit intestinal cytochrome P450 (CYP) isozyme 3A4 and P-glycoprotein (involved in colchicine metabolism and transport). The labeling for colchicine (indicated for acute gout flares or prophylaxis) includes strict advisories regarding drug–drug and drug–food interactions, including warnings against consuming grapefruit or grapefruit juice during treatment. Thus, colored grapefruit juice may produce drug interactions at the same rate as white grapefruit juice.Abstract of research paper on Clinical medicine, author of scientific article - Suman Wason, Jennifer L. White samples inhibited CYP3A-mediated testosterone-6beta oxidation in human liver microsomes by 1.04 and 0.922 times (whole juice and furanocoumarin, respectively) the inhibition by colored juice. The mean difference in bergaptol, bergamottin, and 6',7'-dihydroxybergamottin concentrations in white grapefruit juice samples was 1.59, 0.902, and 1.03 times, respectively, the amounts in colored samples. We measured concentrations of three major furanocoumarin derivatives, bergaptol, bergamottin, and 6',7'-dihydroxybergamottin, with high-performance liquid chromatography in 21 brands of grapefruit juice sold in Japan, including 14 white and 7 colored brands. Therefore, we examined the potential interactions of both white and colored grapefruit products by measuring the concentrations of furanocoumarin derivatives and inhibition of the metabolizing cytochrome P450 (CYP) 3A enzymes, the target of the furanocoumarins. However, few studies have examined interactions with colored juice products. Colored (pink and red) grapefruit pulp contains lower amounts of the furanocoumarin derivatives that cause pharmacokinetic interactions than white grapefruit pulp.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |